Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that aims to provide affordable and accessible personalized immunotherapies for large patient populations. The company, founded in 2020, specializes in developing off-the-shelf, genetically unmodified T cell therapies for a range of conditions, including infectious diseases, cancers, and neurological disorders. Tevogen's proprietary ExacTcell™ platform is a key part of its strategy, which focuses on utilizing natural CD8+ cytotoxic T lymphocytes to target specific antigens on diseased cells. In a move to further accelerate its drug discovery process, the company has also launched Tevogen.AI, its artificial intelligence initiative, which is developing the PredicTcell™ model to enhance target identification and preclinical development, ultimately aiming to reduce the time and cost associated with creating new therapies. Tevogen's business model emphasizes a blend of scientific innovation, business sustainability, and social responsibility to make advanced treatments more widely available.